Lukas Krauß

Meticulous and analytical researcher in the field of cancer biology and epi-genetics. Adaptive team player with in-depth knowledge of data analysis, gene regulation and protein degradation with a keen interest in improving and learning new skills in the field of computational biology.

• Krauss, L.*, Schneider, C., Hessmann, E., Saur, D., Schneider, G.* Epigenetic control of pancreatic cancer metastasis. Cancer Metastasis Rev 42, 1113–1131 (2023).

• Krauss L.*, Urban B.*, Hastreiter S.*, Schneider C.*, et al. "Hdac2 Facilitates Pancreatic Cancer Metastasis." Cancer Res 82.4 (2022): 695-707.

• Abdelsalam M.*, Ibrahim H. S.*, Krauss L*.,et al. "Development of Pyrazine-Anilinobenzamides as Histone Deacetylase Hdac1-3 Selective Inhibitors and Biological Testing against Pancreas Cancer Cell Lines." Methods Mol Biol 2589 (2023): 145-55.

• Orben F., Lankes K., et al. "Epigenetic Drug Screening Defines a Prmt5 Inhibitor-Sensitive Pancreatic Cancer Subtype." JCI Insight 7.10 (2022).

• Schneeweis C., Diersch S., Hassan Z., et al. "Ap1/Fra1 Confers Resistance to Mapk Cascade Inhibition in Pancreatic Cancer." Cell Mol Life Sci 80.1 (2022): 12.

• Lier S., et al. "A Novel Cereblon E3 Ligase Modulator with Antitumor Activity in Gastrointestinal Cancer." Bioorg Chem 119 (2022): 105505.

• Schneeweis C., et al. "Indirect Targeting of Myc Sensitizes Pancreatic Cancer Cells to Mechanistic Target of Rapamycin (Mtor) Inhibition." Cancer Commun (Lond) 42.4 (2022): 360-64

Statistics and R - edX/HarvardX